Compare CMCT & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | FEMY |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 11.5M |
| IPO Year | 1996 | 2021 |
| Metric | CMCT | FEMY |
|---|---|---|
| Price | $5.07 | $1.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 37.9K | ★ 97.6K |
| Earning Date | 11-16-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,669,000.00 | $2,293,313.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $1.78 | $0.29 |
| 52 Week High | $1,441.00 | $6.29 |
| Indicator | CMCT | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 63.87 | 39.05 |
| Support Level | $4.91 | $1.26 |
| Resistance Level | $5.62 | $3.21 |
| Average True Range (ATR) | 0.42 | 0.13 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 90.75 | 52.88 |
Creative Media & Community Trust Corp is a Maryland corporation and REIT. It mainly acquires, develops, owns, and operates both multifamily properties situated in vibrant communities throughout the United States and Class A and creative office real assets in markets with similar business and employment characteristics to multifamily investments. All of its communities are located in areas that include traditional downtowns and suburban main streets, which have high barriers to entry, high population density, positive population trends, and a propensity for growth. Currently, the company consists of three types of commercial real estate properties, namely office, hotel, and multifamily.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.